scholarly journals Creating and screening natural product libraries

2020 ◽  
Vol 37 (7) ◽  
pp. 893-918 ◽  
Author(s):  
Brice A. P. Wilson ◽  
Christopher C. Thornburg ◽  
Curtis J. Henrich ◽  
Tanja Grkovic ◽  
Barry R. O'Keefe

The National Cancer Institute of the United States (NCI) has initiated a Cancer Moonshot program entitled the NCI Program for Natural Product Discovery.

1965 ◽  
Vol 51 (4) ◽  
pp. 227-236
Author(s):  
Umberto Veronesi ◽  
Giorgio Pizzocaro ◽  
Aldo Vittorio Bono

From 1937 to 1960, 1051 women with cystic disease of the breast were hospitalized at the National Cancer Institute of Milan; 1008 of them were followed for a period ranging from 1 to 26 years, with an average of 8.5 years. All cases were histologically proved. Twenty-one of the patients developed a cancer of the breast; 16 in the breast with the cystic disease, 5 in the contralateral breast. In 667 cases the disease was histologically classified as «simple cystic disease »; 12 of these cases had a breast cancer. In 384 cases the disease was classififed as «hyperplastic cystic disease»; 9 of these developed a cancer of the breast. The follow-up of the 1008 cases provided 8539 person-years at risk; the number of the expected breast cases was calculated on the basis of the Dorn and Cutler data on morbidity of cancer in 10 metropolitan areas of the United States. The number of expected breast cancer was 12.2; the number of observed cases was 21, the ratio between observed and expected cases being 1.71.


Endoscopy ◽  
1993 ◽  
Vol 25 (09) ◽  
pp. 617-626 ◽  
Author(s):  
P. Greenwald ◽  
G. Kelloff ◽  
S. Kalagher ◽  
S. McDonald

1994 ◽  
Vol 12 (8) ◽  
pp. 1718-1723 ◽  
Author(s):  
R W Frelick

PURPOSE To review the growth of community physicians' involvement in National Cancer Institute (NCI) clinical research trials as a significant contribution to cancer control, and to show their impact, not yet fully realized, on cancer morbidity and mortality in the United States. DESIGN Background information, based on the personal experience of participants, as well as a review of pertinent literature, portrays the evolution of the clinical research component of community oncology in the United States over the last 25 years. RESULTS Data from Community Clinical Oncology Programs (CCOPs) I and II have been used to outline some of the results of this far-reaching program. CONCLUSION The CCOP was introduced at an appropriate time to expand the clinical trial resources of the NCI, while at the same time helping community oncologists practice state-of-the-art cancer management found in the research protocols. This in turn provided improved resources to manage cancer patients, as most of them are treated in their own communities. CCOPs have also indirectly had a positive impact on the trial processes of the NCI cooperative groups and comprehensive cancer centers, and have helped to widen the scope and hasten progress in cancer-control research and practice.


2008 ◽  
Vol 17 (2) ◽  
pp. 109-115 ◽  
Author(s):  
Donna S. Zhukovsky ◽  
Jessica P. Hwang ◽  
J. Lynn Palmer ◽  
Jie Willey ◽  
Anne L. Flamm ◽  
...  

2020 ◽  
Vol 10 (3) ◽  
pp. 726-729 ◽  
Author(s):  
João Pedro Martins ◽  
José das Neves ◽  
María de la Fuente ◽  
Christian Celia ◽  
Helena Florindo ◽  
...  

Abstract This commentary article conveys the views of the board of the Nanomedicine and Nanoscale Delivery Focus Group of the Controlled Release Society regarding the decision of the United States National Cancer Institute (NCI) in halting funding for the Centers of Cancer Nanotechnology Excellence (CCNEs), and the subsequent editorial articles that broadened this discussion.


Sign in / Sign up

Export Citation Format

Share Document